You've trained hard for decades, and lately the math has changed: the same session takes longer to bounce back from, sleep fragments, and something feels different in a way that's hard to name. If a clinician has waved that away as "normal aging," this is the labs-and-mechanisms version of the conversation you actually wanted.
This article is educational and not medical advice. Decisions about testing and treatment are made by an independent licensed provider who reviews your individual history.
The transition is a moving target, not a single moment
Perimenopause is the years-long hormonal shift leading into menopause, defined by changing cycle length and rising variability — not by a single number. The Endocrine Society and the STRAW+10 staging framework describe it as a transition that can begin in the mid-to-late 40s but sometimes earlier, with hormone levels that swing rather than fall in a clean line [1][2]. That variability is exactly why a single snapshot lab can be misleading, and why "you're too young" is a staging statement, not a verdict.
The practical takeaway for someone lifting through their 40s: estrogen isn't only a reproductive hormone. Estrogen receptors are present in bone, skeletal muscle, and connective tissue, which is part of why the menopause transition coincides with measurable changes in bone density and body composition [3][4].
Source: [2] Executive summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10)
Estradiol and FSH: reading the signal, not one data point
During the transition, follicle-stimulating hormone (FSH) generally trends upward while estradiol becomes erratic before declining [1][2]. A provider typically interprets these together and in the context of cycle timing, because a single FSH or estradiol value drawn on the wrong cycle day can look "normal" even when the broader pattern is shifting. This is the nuance a thorough review adds over a one-off panel.
For bone specifically, the perimenopausal-to-early-postmenopausal window is when the fastest rate of bone loss occurs — research on the menopause transition documents accelerated decline in spine and hip bone mineral density across this period [3]. That's the physiologic reason a provider may pay close attention to bone health here rather than waiting a decade.
Vitamin D: the unglamorous lab that touches muscle and bone
Vitamin D status (measured as serum 25-hydroxyvitamin D) is relevant to both bone mineralization and muscle function. The NIH Office of Dietary Supplements summarizes that deficiency contributes to impaired bone mineralization and that vitamin D supports muscle and calcium metabolism [5]. It's a standard, low-cost marker precisely because deficiency is common and correctable, and because it intersects with the same systems training depends on.
ng/mL · marker = Adequacy threshold
Source: [5] Vitamin D — Health Professional Fact Sheet, NIH Office of Dietary Supplements
Ferritin: the marker that explains stubborn fatigue
For a still-menstruating woman with heavy or unpredictable bleeding — common during the transition — iron stores matter. Ferritin reflects iron storage, and low ferritin (with or without frank anemia) is associated with fatigue and reduced exercise capacity. The NIH iron fact sheet notes that menstruating women are among the groups at higher risk of iron deficiency [6]. If recovery has flattened and energy is low, ferritin is one of the first things worth seeing rather than assuming.
Metabolic markers: lean mass, insulin sensitivity, and the body-composition shift
The menopause transition is independently associated with changes in body composition — increases in fat mass and shifts in fat distribution — beyond what chronological aging alone predicts [4]. That's why a provider may look at metabolic context (for example, fasting glucose, HbA1c, and a lipid panel) alongside hormones. The goal isn't to chase a number; it's to understand whether what you're feeling has a measurable correlate worth addressing — and to separate "expected" from "actionable."
Source: [3] Bone Mineral Density Changes During the Menopause Transition (SWAN), [4] Changes in body composition and weight during the menopause transition (SWAN), [6] Iron — Health Professional Fact Sheet, NIH Office of Dietary Supplements
Where peptides and hormone questions fit (and the honest limits)
Many informed women arrive having read about hormone therapy and about peptides, and want a straight answer. Here's the restraint version: menopausal hormone therapy is an established, evidence-reviewed area, and major societies describe its role in managing transition symptoms for appropriate candidates — a decision an independent provider individualizes based on your history and risks [1].
Peptides are a more heterogeneous category, and many are not FDA-approved drugs; some are available only as compounded preparations. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether any therapy is appropriate — and whether it's prescribed at all — is always decided by an independent licensed provider, and a prescription is never guaranteed.
What a thorough provider review actually looks like
A useful workup treats you as a partner, not a complaint to dismiss. In practice that tends to mean:
- A pattern, not a snapshot. Hormone markers (estradiol, FSH) read in context of cycle timing and symptoms, recognizing that values swing during the transition [1][2].
- The recovery and energy markers. Vitamin D and ferritin, because both connect directly to how you feel in and out of the gym [5][6].
- Metabolic context. Glucose/HbA1c and lipids to understand body-composition and insulin-sensitivity changes that accompany the transition [4].
- A documented plan. What's normal-but-monitorable versus what warrants a next step — and a clear answer to "who reviewed this and why."
The point of all this isn't to medicalize strength. It's to give a serious lifter the data to keep training intelligently — and to make sure a real, accelerated physiologic window (like perimenopausal bone loss) isn't quietly written off as inevitable [3].
Where Velri fits
Velri is a technology and coordination company — not a medical practice. We help you get the relevant labs drawn, route your results and history to an independent, licensed provider for review, and support an unhurried visit where your goals and questions get taken seriously. If — and only if — that independent provider determines a therapy is appropriate, any prescription is fulfilled by an independent licensed pharmacy. Velri does not provide medical care, does not diagnose, and cannot guarantee any specific treatment or outcome. What we coordinate is the logistics; the medicine stays with the clinicians and pharmacists who are licensed to practice it.
This content is educational and is not a substitute for individualized medical advice from a qualified provider.
